RepliCel Closed Final Tranche of Strategic Investment Commitment

Author's Avatar
Dec 22, 2021

VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP, Financial) (FRA:P6P2, Financial) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it has closed the final tranche of the investment by MainPointe Pharmaceuticals ("MainPointe") as outlined in the share purchase agreement signed by the parties earlier this year.